FDA Accepts NDA for Oyster Point’s Dry Eye Therapy OC-01

Submitted by admin on March 2, 2021 - 11:56pm

Source:

BioSpace

News Tags:

Oyster Point

OC-01

dry eye disease

FDA

Headline:

FDA Accepts NDA for Oyster Point’s Dry Eye Therapy OC-01

snippet:

Eye disease company Oyster Point announced the New Drug Application (NDA) for its dry eye disease therapy OC-01, submitted in December, has been accepted for regulatory review on the back of positive Phase III data.

Search form

You are here

FDA Accepts NDA for Oyster Point’s Dry Eye Therapy OC-01

FDA Accepts NDA for Oyster Point’s Dry Eye Therapy OC-01